CARMAT Signs a Partnership Agreement with AddUp, the Michelin and Fives Joint Venture Specialized in 3D Printing
November 13 2017 - 1:00AM
Business Wire
This unique collaboration in the medical sector
will accelerate the industrial phase of the CARMAT project
Regulatory News:
CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and
developer of the world’s most advanced artificial heart project,
aiming to provide a therapeutic alternative for people suffering
from end-stage biventricular heart failure, today announces that it
has signed a partnership agreement with AddUp, the Joint Venture
specialized in 3D printing set up by the Michelin and Fives
groups.
The aim of this collaboration is to strengthen the industrial
development of the CARMAT heart and contribute to increase the
Company’s production capacity in preparation for the large scale
production phase.
Thanks to AddUp’s expertise, CARMAT will ultimately be able to
provide surgeons and patients with a version of its artificial
heart that incorporates all the technological benefits of 3D
printing, and in particular:
- optimized anatomical interfaces leading
to enhanced anatomical compatibility and surgical comfort;
- reduction in the number of components,
thus better securing the device’s assembly.
Vincent Ferreiro, CEO and Chairman of AddUp, comments:
“As pioneers in the development of industrial 3D printing
solutions, we are delighted to have the opportunity to associate
our unique additive manufacturing technology with a medical
project as innovative as the CARMAT one. We possess a know-how in
providing support to our partners from the feasibility stage to the
industrialization of concept ideas. We are very enthusiastic about
the ability to apply it to the medical field for the first
time.”
Stéphane Piat, CEO of CARMAT, adds: “The CARMAT project
has been, since the beginning, a perfect example of cooperation
between the industrial and medical fields. The partnership
agreement signed today with AddUp is an additional proof and will
enable us – alongside our ongoing clinical development – to
anticipate longer-term evolutions in our industrial and technical
needs. With a partner as prestigious as AddUp, I am convinced in
our ability to accelerate our industrialization and secure our
project.”
●●●
About AddUp
AddUp was created on April 1, 2016 following the decision
adopted by the two major industrial groups Fives and Michelin to
create, on September 4, 2015, Fives Michelin Additive Solutions.
This joint venture aims to bring customers its unique experience
and expertise in developing and marketing machines and industrial
production lines using metal additive manufacturing technology,
generally known as metal 3D printing, worldwide.
About CARMAT: the world’s most advanced total artificial
heart project
A credible response to end-stage heart failure: CARMAT
aims to eventually provide a response to a major public health
issue associated with heart disease, the world’s leading cause of
death: chronic and acute heart failure. By pursuing the development
of its total artificial heart, CARMAT intends to overcome the
well-known shortfall in heart transplants for the tens of thousands
of people suffering from irreversible end-stage heart failure, the
most seriously affected of the 20 million patients with this
progressive disease in Europe and the United States.
The result of combining two types of unique expertise:
the medical expertise of Professor Carpentier, known throughout the
world for inventing Carpentier-Edwards® heart valves, which
are the most used in the world, and the technological expertise of
Airbus Group, world aerospace leader.
Imitating the natural heart: given its size, the choice
of structural materials and its innovative physiological functions,
CARMAT’s total artificial heart could, assuming the necessary
clinical trials are successful, potentially benefit the lives of
thousands of patients a year with no risk of rejection and with a
good quality of life.
A project leader acknowledged at a European level: with
the backing of the European Commission, CARMAT has been granted the
largest subsidy ever given to an SME by Bpifrance; a total of €33
million.
Strongly committed, prestigious founders and
shareholders: Airbus Group (Matra Défense), Professor Alain
Carpentier, the Centre Chirurgical Marie Lannelongue,Truffle
Capital, a leading European venture capital firm, ALIAD, Air
Liquide’s venture capital investor, CorNovum, an investment holding
company held 50-50 by Bpifrance and the French State, the family
offices of Pierre Bastid (ZAKA) and of Dr. Antonino Ligresti (Santé
Holdings S.R.L.) as well as the thousands of institutional and
individual shareholders who have placed their trust in CARMAT.
For more information: www.carmatsa.com
●●●
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe to, or a solicitation of
an offer to buy or subscribe to, shares in CARMAT ("the Company")
in any country. This press release contains forward‐looking
statements that relate to the Company’s objectives. Such
forward‐looking statements are based solely on the current
expectations and assumptions of the Company’s management and
involve risk and uncertainties. Potential risks and uncertainties
include, without limitation, whether the Company will be successful
in implementing its strategies, whether there will be continued
growth in the relevant market and demand for the Company’s
products, new products or technological developments introduced by
competitors, and risks associated with managing growth. The
Company’s objectives as mentioned in this press release may not be
achieved for any of these reasons or due to other risks and
uncertainties.
No guarantee can be given as to any of the events anticipated by
the forward-looking statements, which are subject to inherent
risks, including those described in the Document de Référence filed
with the Autorité des Marchés Financiers under number D.16-0200 on
March 22, 2017 and changes in economic conditions, the financial
markets or the markets in which CARMAT operates. In particular, no
guarantee can be given concerning the Company’s ability to finalize
the development, validation and industrialization of the prosthesis
and the equipment required for its use, to manufacture the
prostheses, satisfy the requirements of the ANSM, enroll patients,
obtain satisfactory clinical results, perform the clinical trials
and tests required for CE marking and to obtain the CE mark. CARMAT
products are currently exclusively used within the framework of
clinical trials.
●●●
Name: CARMATISIN code:
FR0010907956Ticker: ALCAR
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171112005047/en/
CARMATStéphane PiatCEOBenoît de la
MotteCFOTel. : +33 (0)1 39 45 64
50contact@carmatsas.comorAddUpVincent FerreiroCEO and
ChairmanJean-Luc LAVALPress RelationsMarketing and
Communication DirectorJean-luc.laval@addupsolutions.comorAlize
RPPress RelationsCaroline Carmagnol, Tel. : +33 (0)1 44
54 36 66carmat@alizerp.comorNewCapInvestor Relations &
Strategic CommunicationDusan OresanskyEmmanuel
HuynhTel. : +33 (0)1 44 71 94 94carmat@newcap.fr
Carmat (EU:ALCAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Carmat (EU:ALCAR)
Historical Stock Chart
From Apr 2023 to Apr 2024